Meeting
2022 ASCO Annual Meeting
A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Authors
Jermaine Coward
ICON Cancer Centre, South Brisbane, QLD, Australia
Jermaine Coward , Ben Markman , Adnan Nagrial , Afaf Abed , Imogen Walpole
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT04481009
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2603)
DOI
10.1200/JCO.2022.40.16_suppl.2603
Abstract #
2603
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
First Author: Vinod Ganju
Poster
2021 ASCO Annual Meeting
Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
First Author: Jermaine Coward
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.
First Author: Jayesh Desai